Anti-HIV antibodies
AssigneeInternational AIDS Vaccine Initiative
InventorsElise Landais, Devin Sok
Life of this patent
Estimating the term…
Abstract
Provided herein are anti-HIV Env antibodies and their use in the treatment or prevention of HIV/AIDS.
Claims16
A method of neutralizing a human immunodeficiency virus (HIV) comprising contacting the virus with a sufficient amount of an isolated monoclonal antibody that specifically binds to HIV envelope glycoprotein (Env) and comprises a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1), VH CDR2, and VH CDR3 and a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3, wherein
- (a) the VH CDR1 comprises any one of the amino acid sequences of SEQ ID NOs:
- 1-18;
- (b) the VH CDR2 comprises any one of the amino acid sequences of SEQ ID NOs:
- 19-36;
- (c) the VH CDR3 comprises any one of the amino acid sequences of SEQ ID NOs:
- 37-54;
- (d) the VL CDR1 comprises any one of the amino acid sequences of SEQ ID NOs:
- 55-72;
- (e) the VL CDR2 comprises any one of the amino acid sequences of SEQ ID NOs:
- 73-90;
- and
- (f) the VL CDR3 comprises any one of the amino acid sequences of SEQ ID NOs:
- 91-108.
A method for passively immunizing a subject comprising administering to the subject in need thereof an effective amount of a monoclonal antibody or an isolated polynucleotide encoding the antibody, wherein the antibody specifically binds to human immunodeficiency virus envelope glycoprotein (HIV Env) and comprises a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1), VH CDR2, and VH CDR3 and a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3, wherein
- (a) the VH CDR1 comprises any one of the amino acid sequences of SEQ ID NOs:
- 1-18;
- (b) the VH CDR2 comprises any one of the amino acid sequences of SEQ ID NOs:
- 19-36;
- (c) the VH CDR3 comprises any one of the amino acid sequences of SEQ ID NOs:
- 37-54;
- (d) the VL CDR1 comprises any one of the amino acid sequences of SEQ ID NOs:
- 55-72;
- (e) the VL CDR2 comprises any one of the amino acid sequences of SEQ ID NOs:
- 73-90;
- and
- (f) the VL CDR3 comprises any one of the amino acid sequences of SEQ ID NOs:
- 91-108.
A method of treating human immunodeficiency virus/acquired immunodeficiency syndrome comprising administering to a subject in need thereof a therapeutically sufficient amount of a monoclonal antibody or an isolated polynucleotide encoding the antibody, wherein the antibody specifically binds to human immunodeficiency virus envelope glycoprotein (HIV Env) and comprises a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1), VH CDR2, and VH CDR3 and a light chain variable region (VL) comprising a VL CDR1, VL CDR2, and VL CDR3, wherein
- (a) the VH CDR1 comprises any one of the amino acid sequences of SEQ ID NOs:
- 1-18;
- (b) the VH CDR2 comprises any one of the amino acid sequences of SEQ ID NOs:
- 19-36;
- (c) the VH CDR3 comprises any one of the amino acid sequences of SEQ ID NOs:
- 37-54;
- (d) the VL CDR1 comprises any one of the amino acid sequences of SEQ ID NOs:
- 55-72;
- (e) the VL CDR2 comprises any one of the amino acid sequences of SEQ ID NOs:
- 73-90;
- and
- (f) the VL CDR3 comprises any one of the amino acid sequences of SEQ ID NOs:
- 91-108.
Dependencies are inferred from the claim text.